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Purpose: To evaluate the use of aflibercept, triamcinolone acetonide, and photodynamic 
therapy (PDT) in the treatment of avascular pigment epithelium detachments (aPEDs).
Patients and methods: Patients with treatment-naïve aPEDs $1,500 µm in diameter were 
randomized to treatment or observation. Treatment consisted of 6 monthly intravitreal injections 
of aflibercept. If the aPED persisted, the patients were treated with half-fluence PDT in combina-
tion with intravitreal triamcinolone acetonide and aflibercept. The primary outcome was change 
of best-corrected visual acuity (BCVA) after 24 months of follow-up. Secondary outcomes 
were changes in pigment epithelium volume, height and diameter, central retinal thickness, 
and number of patients developing choroidal neovascularization or geographic atrophy (GA).
Results: Treatment and inclusion of patients were stopped after an interim analysis of 
6-month data because 75% of the aPEDs were in different stages of GA. Nine patients with 
aPED were included in the study, of these one patient was excluded because of bilateral 
central serous chorioretinopathy. The remaining eight had drusenoid aPEDs. After 24 months 
of follow-up, estimated means of BCVA decreased by 4.2 and 20.8 letters in the treatment 
and observation group, respectively. This decrease over time was not significantly different 
between groups (P=0.140, 95% CI -5.3, 38.6). Estimated means of PED volume, height, 
diameter, and central retinal thickness were not significantly different between groups. Cho-
roidal neovascularization and retinal pigment epithelium tear developed in one patient in the 
treatment group. One patient in the treatment group and two patients in the observation group 
progressed to complete retinal pigment epithelium and outer retinal atrophy. A decrease in 
PED volume was associated with the development of complete retinal pigment epithelium 
and outer retinal atrophy (P=0.029).
Conclusion: This small trial indicates that multitargeted, primarily antiangiogenic therapy 
does not favorably alter the natural course of drusenoid aPEDs.
Keywords: drusenoid, geographic atrophy, anti-VEGF, PDT
Plain language summary
How to manage large accumulations of lipids and fluid in the part of your eye responsible for 
good vision, without associated leaking blood vessels, is not fully understood. Their presence 
is associated with a risk of visual impairment. Available treatments (anti-vascular endothelial 
growth factor and photodynamic therapy) have in small studies and case reports shown some 
beneficial effects.
We investigated if treatment could be beneficial by designing a study with patients randomly 
assigned to treatment or observation. Treatment consisted of injecting the eye with anti-vascular 
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endothelial growth factor monthly for 6 months, and then adding 
photodynamic therapy and injections of corticosteroids if the 
accumulation of lipids and fluid did not resolve. Our study was 
stopped early when 6 months data were available because 75% of 
the patients progressed to a more advanced form of the disease with 
no currently available treatment.
This small study indicates that treatment with a combination 
of anti-vascular endothelial growth factor, corticosteroid, and 
photodynamic therapy does not favorably alter the natural course 
of large accumulations of lipids and fluid in age-related macular 
degeneration without associated leaking blood vessels.
Introduction
Age-related macular degeneration (AMD) is the most com-
mon cause of permanent vision loss in the industrialized 
world.1–3 With the introduction of anti-vascular endothelial 
growth factor (anti-VEGF) agents, treatment for neovascular 
AMD (nAMD) has undergone significant advances. There 
are still dilemmas to be solved, and research on biomarkers 
relevant for visual function, disease activity, and prognosis 
is desirable.4 One such biomarker, pigment epithelium 
detachment (PED), is still a challenge, both in avascular PED 
(aPED) and when neovascularization is present (nPED). The 
pathophysiologic mechanisms underlying the development 
of PEDs are not fully understood, and probably represent a 
continuum of degenerative changes and formation of cho-
roidal neovascularization (CNV).5 Serous aPEDs are thought 
to arise from age-related formation of a hydrophobic barrier 
in Bruch’s membrane preventing the free diffusion of fluid 
from retinal pigment epithelium (RPE) to choriocapillaris.6 
Drusenoid aPED formation is a result of the confluence of 
large drusen, and probably with increasing size the hydro-
phobic composition of the drusenoid deposits also creates a 
barrier in Bruch’s membrane with accumulation of fluid.7,8
In some retrospective case series, nPEDs respond well 
to treatment with anti-VEGF.9–11 In other studies, the results 
are not so promising,12 and nPEDs might be more resis-
tant to treatment.4 Nonresponders to anti-VEGF treatment 
have the option of photodynamic therapy (PDT), which 
has been shown to stabilize disease progression,13 but the 
treatment may lead to chorioretinal atrophy and decline in 
visual acuity.14
The natural course of aPED is unfavorable. In the Age-
Related Eye Disease Study, it was found that 42% of 282 
eyes with drusenoid aPEDs progressed to advanced AMD, 
with either central geographic atrophy (GA) (19%) or nAMD 
(23%).15 In one study with long follow-up of 12 eyes with 
drusenoid aPED, all patients developed advanced AMD, with 
a 10-year occurrence rate of 75% for central GA and 25% for 
nAMD.8 Patients presenting with aPEDs remain a diagnostic 
and therapeutic challenge, and treatment is controversial.12 
One prospective case series treated 12 drusenoid and serous 
aPEDs with anti-VEGF, which led to stabilization of best-
corrected visual acuity (BCVA) after 1 year, but with het-
erogeneous anatomical outcomes.16 In another prospective 
case series, six patients with drusenoid aPEDs were treated 
with anti-VEGF agents that led to stabilization of BCVA 
and improvement in 33% of patients.17 Two case reports 
have reported regression of drusen and drusenoid PEDs fol-
lowing anti-VEGF treatment for associated CNV.18,19 Other 
case reports have shown regression of drusenoid aPED and 
improvement of BCVA after PDT.20,21
In the present study, we planned to evaluate the treatment 
of serous and drusenoid aPEDs. Our original hypothesis was 
that some aPEDs may be caused by subtle CNV, undetect-
able with today’s technology, and that early treatment could 
be beneficial. To our knowledge, this is the first randomized 
controlled trial evaluating treatment of aPEDs with afliber-
cept, PDT, and triamcinolone acetonide.
Patients and methods
The study was conducted at the Department of Ophthalmol-
ogy, Trondheim University Hospital, and the inclusion of 
patients started in April 2014. Patients with AMD and large 
PEDs, that on clinical evaluation seemed to be avascular, 
were referred from other eye departments and ophthalmolo-
gists in the Central Norway Health Region. The study is 
registered at ClinicalTrials.gov: NCT01746875, and was 
approved by the Regional Committee for Medical and 
Health Research Ethics Central Norway (2012/1743). All 
study participants provided a written informed consent, and 
the study was conducted in accordance with the Declaration 
of Helsinki.
Inclusion criteria were patients older than 50 years with 
treatment-naïve AMD, fluorescein angiographic (FA)- and 
indocyanine green angiographic (ICG)-verified subfo-
veal aPED $1,500 µm in diameter, and BCVA #20/32 
and $20/400. Exclusion criteria were subfoveal fibrosis, 
central GA, and concurrent eye diseases that could affect 
BCVA.
The diagnosis of aPED was made by FA, ICG, and 
spectral-domain optical coherence tomography (OCT). 
PEDs with no leakage on FA and an absence of plaques and 
hot spots on ICG were defined as aPEDs. The aPEDs were 
defined as drusenoid if they appeared yellow on clinical fundus 
examination with predominantly hyper-reflective contents on 
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The aPEDs were defined as serous if they appeared as dome-
shaped with predominantly hyporeflective contents on OCT, 
pooling on FA, and hypofluorescence on ICG. Central GA 
was defined as an area with window defects on FA and ICG, 
sharply delineated margins on fundus photography with vis-
ible choroidal vasculature, loss of a hyper-reflective RPE line, 
and increased choroidal reflectivity on OCT, hypofluorescence 
on fundus autofluoresence (FAF), and subfoveal localization.
Fundus and angiographic images (Zeiss FF 450 plus, 
Carl Zeiss Meditec AG, Jena, Germany) were reviewed and 
graded by two retina specialists (AT and DA). To ensure 
a correct diagnosis, all the images were also anonymized 
and sent for evaluation to an external retina specialist (CH) 
prior to randomization. Randomization was performed by a 
web-based randomization system developed and adminis-
tered by Unit of Applied Clinical Research, The Faculty of 
Medicine, Norwegian University of Science and Technology, 
Trondheim, Norway. The patients were stratified on the pres-
ence of drusenoid aPED.
BCVA was measured using Early Treatment Diabetic 
Retinopathy Study (ETDRS) chart in an illuminated Cabinet 
(ESV3000; Good-Lite, Elgin, IL, USA) at 4 m, with auto-
matic adjustment of 85 cd/m2. Room lighting was dimmed 
so that 90–110 lux could be measured in front of the cabinet. 
The examiners were blinded for patient group. Refraction was 
performed by a physician or optician prior to BCVA measure-
ment at baseline, 1 year, and 2 years. Maximum PED height 
and diameter were measured by OCT (Cirrus HD-OCT; Carl 
Zeiss Meditec AG) on five different slides on macular cube 
scans starting in the central fovea (512×128), and the mean 
of the three highest values was used. PED volume was cal-
culated after manual segmentation and subtracting of total 
retinal and PED volume, measured from the internal limiting 
membrane (ILM) to the fit-RPE line, with retinal volume, 
measured from ILM to RPE line (Figure 1). Central retinal 
thickness (CRT) was obtained automatically after manual 
segmentation of RPE and ILM.
Patients randomized to the treatment group received three 
monthly intravitreal injections of aflibercept 2 mg/0.05 mL 
(Eylea; Regeneron Inc., Tarrytown, NY, USA), with 3 addi-
tional monthly injections if the PED persisted at 3 months. If 
the PED did not completely resolve as measured by OCT, the 
patients were treated with half-fluence PDT in combination 
with aflibercept 2 mg/0.05 mL and triamcinolone acetonide 
4 mg/0.1 mL (Triesence; Alcon lab Inc., Forthworth, TX, 
USA) at 6 and 9 months (triple-therapy). The half-fluence 
PDT treatment protocol consisted of intravenous administra-
tion of 15 mg Verteporfin (Visudyne; Bausch and Lomb Inc., 
Bridgewater, NJ, USA) in a 30 mL solution over 10 minutes, 
and after a waiting period of 5 minutes, infrared light (689 
nm) with a spot size of 3,000–4,000 µm was applied for 
83 seconds with 25 J/cm2 and 300 mW/cm2 (Visulas 690s, 
Carl Zeiss Meditec AG). Intravitreal injections of aflibercept 
and triamcinolone acetonide were given on separate days 
0–2 weeks after the PDT treatment. Additional follow-up 
examinations were performed at 6-month intervals in both 
groups and included BCVA measurements, OCT, fundus 
photography, FA, ICG, and FAF.
The primary outcome measure was changes in BCVA 
from baseline to 24 months. Secondary outcome measures 
were changes in PED height, diameter and volume, CRT, and 
number of patients with progression of GA or development of 
CNV. Progression of GA was graded as described by Sadda 
et al22: complete RPE and outer retinal atrophy (cRORA); 1) 
region of hypertransmission of at least 250 µm in diameter in 
any lateral dimension, 2) zone of attenuation or disruption of 
the RPE of at least 250 µm in diameter, 3) evidence of over-
lying photoreceptor degeneration. Features of photoreceptor 
degeneration include all of the following: loss of interdigita-
tion zone, ellipsoid zone, and external limiting membrane, 
and thinning of the outer nuclear layer, which also can be 
identified by a descending outer plexiform layer. In case 
of incomplete RPE and outer retinal atrophy (iRORA), the 
criteria for cRORA are not met, but hypertransmission and 
Figure 1 Manual segmentation and volume measurement of retinal pigment epithelium detachment from macular cube 512×128 scans.
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a discontinuous RPE band with evidence of photoreceptor 
degeneration are found. Exclusion criteria were presence of 
scrolled RPE or other signs of an RPE tear.
A sample size of 60 patients was decided to be suffi-
cient to detect a clinically meaningful difference. Marginal 
models with restricted maximum likelihood estimation and 
unstructured or exponential covariance structure were used. 
All marginal models had age, baseline value, group, time, 
and the interaction between group and time as predictors. 
The P-values and 95% CIs of the comparisons of estimated 
means were Sidak adjusted because of multiple comparisons. 
Model fit was evaluated with Akaike’s information criterion 
and likelihood ratio tests. The residuals were checked for 
normality compared to the normal distribution assessed with 
histograms, Q–Q plots, and Shapiro–Wilks test. Two-tailed 
P-values ,0.05 were considered statistically significant. 
SPSS statistics 25 (IBM) and Stata 15.1 (StataCorp LLC) 
were used for statistical analysis.
Results
A total of 14 patients with AMD and aPED $1,500 µm in 
diameter were referred from April 2014 to February 2015. 
Of these, five patients did not meet the inclusion criteria. 
Two patients with serous PED, one with fibrovascular PED 
and one with drusenoid PED, had CNV. One patient had 
adult-onset foveomacular vitelliform dystrophy. Thus, nine 
patients with aPEDs were included in the study, with five 
randomized to the treatment group. One patient from the 
treatment group was excluded after 3 months of follow-up 
because of disappearance of bilateral serous aPEDs after 
tapering of systemic corticosteroid therapy on suspicion of 
central serous chorioretinopathy. Baseline characteristics 
of the eight drusenoid aPEDs are summarized in Table 1.
An interim analysis was performed after 6 months of 
follow-up. Because examination of the OCT images showed 
that the patients in both the treatment and observation groups 
were in different stages of GA formation and progression 
(Figure 2), it was decided to stop further inclusion and treat-
ment of patients.
The four participants in the treatment group received 
6 monthly injections of aflibercept, but further treatment 
differed. Two patients (Figure 2, ID: 2 and 3) received both 
treatments with triple-therapy, one patient had only one treat-
ment (Figure 2, ID: 7) and one patient did not receive triple- 
therapy (Figure 2, ID: 5). All patients were followed for 
12 months (mean 12.4, range 12–13), and three patients 
in each group had a follow-up of 24 months (mean 24.2, 
range 24–25).
Best-corrected visual acuity
After 24 months of follow-up, estimated means of BCVA 
decreased by 4.2 ETDRS letters and 20.8 ETDRS letters in the 
treatment and observation groups, respectively (Figure 3A). 
The loss of ETDRS letters from 6 to 24 months did not differ 
significantly between groups (P=0.140, 95% CI -5.3, 38.6). 
After 6, 12, and 24 months of follow-up, the difference 
of BCVA was 0.8 ETDRS letters (P=1.0, 95% CI -21.3, 
22.8), 0.3 ETDRS letters (P=1.0, 95% CI -21.8, 22.3), and 
17.4 ETDRS letters (P=0.478, 95% CI -7.7, 42.4) between 
the treatment and observation groups, respectively. Follow-
up duration and age of patients were significant predictors 
of decreasing BCVA (P=0.048 and P=0.009, respectively). 
BCVA at baseline was not a significant predictor (P=0.593).
PeD volume
After 24 months of follow-up, estimated means of PED 
volume increased by 0.13 mm3 in the treatment group and 
decreased by 0.13 mm3 in the observation group (Figure 3B). 
The change of PED volume from 6 to 24 months did not 
differ significantly between the groups (P=0.433, 95% 
CI -0.40, 0.91). After 6, 12, and 24 months of follow-up, 
differences in PED volume were 0.22 mm3 (P=1.0, 95% 
Table 1 Baseline characteristics of drusenoid aPEDs
Treatment (n=4) Observation (n=4)
Mean SD Median Min Max Mean SD Median Min Max
Age, years 76.8 7.4 76 69 86 73.8 7.8 74 64 83
BCVA, ETDRS letters 65.0 7.0 65.0 58 72 66.8 6.5 70.0 57 70
PeD           
Height, µm 279 106 284 160 387 345 53 338 298 406
Diameter, µm 2,657 1,124 2,243 1,848 4,293 2,275 258 2,276 2,012 2,535
Volume, mm3 0.98 0.83 0.65 0.40 2.20 0.90 0.50 0.75 0.50 1.60
CRT, µm 218 3.7 219 213 222 199 12.7 204 180 208
Abbreviations: aPED, avascular pigment epithelium detachment; BCVA, best-corrected visual acuity; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic 
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Figure 2 grading of ga by OCT.
Notes: (i) Photoreceptor degeneration. (ii) attenuation or disruption of rPe. (iii) hypertransmission. (iv) Descending outer plexiform layer. (v) scrolled up rPe. 
(vi) subretinal drusenoid material.
Abbreviations: CNM, criteria for iRORA/cRORA not met; cRORA, complete RPE and outer retinal atrophy; ID, patient number; iRORA, incomplete RPE and outer retinal 
atrophy; RPE, retinal pigment epithelium; OCT, optical coherence tomography; GA, geographic atrophy.
CI -1.12, 1.56), 0.27 mm3 (P=0.99, 95% CI -0.63, 1.17), and 
0.48 mm3 (P=0.487, 95% CI -0.22, 1.18) between the treat-
ment and observation groups, respectively. Age of patients 
was a significant predictor of decreasing PED volume 
(P=0.043, 95% CI -0.07, -0.001). A larger baseline value 
significantly predicted a larger follow-up PED volume 
(P,0.001, 95% CI 1.53, 2.20). Follow-up duration was not 
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Figure 3 Estimated means of BCVA, PED volume, height and diameter, and CRT from 6 to 24 months.
Notes: (A) BCVA; the rightmost y-axis corresponds to Snellen equivalent. (B) PeD volume. (C) PeD height. (D) PeD diameter. (E) CrT. The error bars represent 95% 
Cis (n=22 observations on eight patients).
Abbreviations: BCVA, best-corrected visual acuity; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; mo., months; PED, pigment 
epithelium detachment.
PeD height
After 24 months of follow-up, estimated means of PED 
height decreased by 88.3 and 72.8 µm in the treatment and 
observation groups, respectively (Figure 3C). The change of 
PED height from 6 to 24 months did not differ significantly 
between the groups (P=0.842, 95% CI -168.6, 137.5). After 
6, 12, and 24 months of follow-up, differences in PED 
height were 168.8 µm (P=0.949, 95% CI -199.7, 537.4), 
139.6 µm (P=0.991, 95% CI -229.0, 508.1), and 153.3 µm 
(P=0.983, 95% CI -226.7, 533.2) between the treatment and 
observation groups, respectively. Age of patients, baseline 
PED height, and duration of follow-up were not significant 
predictors (P=0.483, P=0.075, and P=0.188, respectively).
PeD diameter
After 24 months of follow-up, estimated means of PED 
diameter decreased by 544 and 856 µm in the treatment 
and observation groups, respectively (Figure 3D). The 
change of PED diameter from 6 to 24 months did not dif-
fer significantly between the groups (P=0.603, 95% CI 
-863, 1,487). After 6, 12, and 24 months of follow-up, 
differences in PED diameter were 589 µm (P=1.000, 95% 
CI -1,478, 2,655), 627 µm (P=0.99, 95% CI -1,440, 2,693), 
and 900 µm (P=0.976, 95% CI -1,247, 3,048) between the 
treatment and observation groups, respectively. Baseline 
diameter and duration of follow-up were significant predic-
tors of decreasing PED diameter (P=0.022 and P=0.044, 
respectively). Age of patients was not a significant predic-
tor (P=0.218).
Central retinal thickness
After 24 months of follow-up, estimated means of CRT 
decreased by 20.3 and 22.7 µm in the treatment and observa-
tion groups, respectively (Figure 3E). The change in CRT 
from 6 to 24 months did not differ significantly between 
the groups (P=0.852, 95% CI -22.8, 27.6). After 6, 12, and 
24 months of follow-up, the differences in CRT were -5.9 µm 
(P=1.000, 95% CI -35.9, 24.0), -18.4 µm (P=0.671, 95% 
CI -48.4, 11.5), and -3.5 µm (P=1.000, 95% CI -40.8, 33.8) 
between the treatment and observation groups, respectively. 
Age of patients and duration of follow-up were significant 
predictors of decreasing CRT (P,0.001 and P=0.019, 
respectively). A larger baseline value significantly predicted 
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GA (defined as iRORA or cRORA) was present in 38%, 
75%, 71%, and 86% of patients at baseline and at 6, 12, and 
24 months follow-up in both groups combined (Figure 2). 
After 24 months of follow-up, two patients in the observa-
tion group and one patient in the treatment group progressed 
to cRORA. One patient had identifiable cRORA at baseline 
in the observation group. A decrease in PED volume was 
significantly associated with the development of cRORA 
(Fisher’s exact test, P=0.029).
safety outcomes
There were no cases of endophthalmitis or retinal detachment 
after the intravitreal injections. Two weeks after injection of 
triamcinolone acetonide, mean IOP was 13 mmHg (ranging 
from 11 to 16 mmHg). At baseline, 6 months, 12 months, and 
24 months, mean IOP was 16, 15, 13, and 12 mmHg in the 
treatment group. One patient in the treatment group (Figure 2, 
ID: 2) was diagnosed with CNV after the first treatment with 
half-fluence PDT, and was subsequently treated with full-
fluence PDT, which led to the development of an RPE tear.
Two patients in the treatment group and one patient in 
the observation group had an increase of nuclear sclerosis 
from grade 1 to grade 2 by the end of follow-up. One patient 
in the observation group (Figure 2, ID: 4) had cataract 
surgery between 12 and 24 months of follow-up, with no 
improvement of BCVA because of progression of GA to 
cRORA.
Discussion
In the present study, we originally set out to investigate the 
treatment of both serous and drusenoid aPEDs. However, 
the referred patients with serous PEDs were either excluded 
because of CNV or central serous chorioretinopathy. The 
higher risk of CNV in serous PEDs has previously been 
reported. In a retrospective study, 34% of serous and 9% 
of drusenoid PEDs developed CNV.23 In two prospective 
studies, 32% of serous aPEDs developed CNV after a mean 
follow-up of 19.6 months,24 and 23% of drusenoid aPEDs 
developed CNV over a 5-year period.15
Further inclusion and treatment of aPEDs were stopped 
after the interim analysis of 6 months data. Examination 
of OCT images showed that 75% of patients in our study 
were in different stages of GA formation and progres-
sion.25 Treatment with anti-VEGF or PDT is not a viable 
treatment option for GA, and it is still unclear if the use 
of anti-VEGF agents increases its progression.26 PDT has 
not been shown to directly damage the photoreceptors or 
RPE. However, PDT induces a selective occlusion of the 
choriocapillaris,27 which in turn could lead to atrophy of 
RPE and photoreceptors.
BCVA decreased during follow-up with no significant 
differences between groups. The observation group had a 
greater, although insignificant, loss of ETDRS letters, prob-
ably due to the presence of cRORA in three of four patients. 
Duration of follow-up was a significant predictor of BCVA 
loss, and this indicates that this study mainly observed the 
natural course of drusenoid aPEDs. Our results differ from 
two prospective studies treating aPEDs with anti-VEGF 
agents, which resulted in stabilization or improvement 
of BCVA and no progression of GA or development of 
CNV.16,17 The drusenoid aPEDs in our treatment group 
were larger (mean 0.98 mm3) than in the study conducted 
by Ritter et al (mean 0.38 mm3).16 Large drusenoid aPEDs 
are probably a sign of more advanced AMD with worse 
prognosis. Interestingly, the two largest aPEDs in the pres-
ent study did not progress to cRORA during follow-up, 
suggesting that PED volume is not the only risk factor for 
the progression of GA.
Drusenoid aPEDs are thought to be caused by the 
confluence of soft drusen over time,5,7 which represents a 
risk factor for progression of GA or development of CNV.8 
In our study, progression of GA to cRORA was identified 
in 50% of patients, and development of cRORA was sig-
nificantly associated with a reduction in PED volume. This 
is in line with the proposed lifecycle of drusenoid aPEDs 
with a growth and regression phase that ultimately leads 
to GA.28,29 It has been proposed that an increased distance 
from the RPE to the choriocapillaris in drusenoid aPEDs has 
a negative impact on the RPE, leading to RPE atrophy and 
outer retinal atrophy.30 This theory seems plausible as dis-
ruptions of the RPE layer and photoreceptors predominantly 
occur at the apex of drusenoid aPEDs, which is the point 
of greatest distance to the choriocapillaris.28 A reduction in 
PED volume and distance between the choriocapillaris and 
RPE may improve the metabolism of the RPE and outer 
retina. However, a reduction in PED volume will probably 
only have a positive impact on the RPE and the outer retina 
if it occurs prior to the progression of GA to cRORA. Two 
studies on rheopheresis (extracorporeal plasma filtration) 
in the treatment of drusenoid aPEDs have shown interest-
ing results with improvement of BCVA, a decrease of 
drusenoid PED volume, and a reduced number of patients 
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Future studies evaluating new treatment modalities for 
drusenoid aPEDs should probably aim to reduce PED vol-
ume, and assess with high-resolution OCT if the frequency 
of GA progression to cRORA is reduced.
Conclusion
Although limited by the low number of participants, 
the present study indicates that multitargeted, primarily 
antiangiogenic therapy does not favorably alter the natural 
course of large drusenoid aPEDs.
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Anti-VEGF, anti-vascular endothelial growth factor; aPED, 
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corrected visual acuity; CNV, choroidal neovascularization; 
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